Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for Phase 2 Trial of LYR-210 for Chronic Rhinosinusitis

Lyra Therapeutics announced the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LYR-210 for the treatment of chronic rhinosinusitis (CRS). Lyra plans to incorporate U.S. clinical sites into LANTERN, its ongoing global Phase 2 clinical...

Margaret Rosenfeld, MD, MPH, Seattle Children’s Research Institute and Department of Pediatrics, University of Washington School of Medicine

Dr. Rosenfeld was a lead investigator in the Phase 3 ARRIVAL study, sponsored by Vertex, which found Ivacaftor (KALYDECO®) is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. Dr. Rosenfeld noted...

Pin It on Pinterest